Aug. 5 at 5:30 PM
$KRYS drops 14% despite Q2 beat — what's behind the slide? 📉
Krystal Biotech reported EPS of
$1.29, topping the Zacks Consensus Estimate of
$1.08, and revenues from sales of Vyjuvek surged 36.6% YoY. However, soft guidance for third-quarter revenues spooked investors, leading to the decline.
Full breakdown here 👉 https://www.zacks.com/stock/news/2667254/krys-q2-earnings-and-sales-top-estimates-stock-down-on-q3-outlook?cid=sm-stocktwits-2-2667254-body-5966&ADID=SYND_STOCKTWITS_TWEET_2_2667254_BODY_5966